Erre, Gian Luca and Pardini, Simonetta and Cuccuru, Luciana and Taras, Loredana and Passiu, Giuseppe (2015) Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis? Joint Bone Spine, Vol. 82 (1), p. 72-73. ISSN 1297-319X. Article.
Full text not available from this repository.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic eosinophilic vasculitis, belonging to the group of ANCA-associated vasculitides (AAV). EGPA pathogenesis is still elusive, but a potential role for IL-5 and Eotaxins mediated eosinophil activation has been reported. Imatinib mesylate, a tyrosine kinase (TK) inhibitor, is approved for the treatment of chronic myeloid leukaemia and FIP1L1/PDGFRA positive gene fusion hypereosinophilia. A potential role for imatinib in the treatment of idiopathic hypereosinophilic syndrome (HES) and AAV has been recently proposed.
I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore
Repository Staff Only: item control page